bioAffinity Technologies (NASDAQ:BIAF) Posts Earnings Results

bioAffinity Technologies (NASDAQ:BIAF) announced its quarterly earnings data on Friday. The company reported ($1.11) EPS for the quarter, FiscalAI reports. bioAffinity Technologies had a negative return on equity of 425.87% and a negative net margin of 217.45%.The business had revenue of $1.59 million during the quarter.

bioAffinity Technologies Stock Performance

Shares of NASDAQ BIAF opened at $2.12 on Friday. The stock has a 50 day moving average price of $1.16 and a 200 day moving average price of $2.48. bioAffinity Technologies has a 52 week low of $0.69 and a 52 week high of $46.53. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.65. The stock has a market capitalization of $9.54 million, a PE ratio of -0.10 and a beta of 2.42.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Sabby Management LLC bought a new stake in shares of bioAffinity Technologies during the 3rd quarter worth approximately $719,000. Scientech Research LLC bought a new position in shares of bioAffinity Technologies in the third quarter valued at $49,000. Finally, Geode Capital Management LLC bought a new position in shares of bioAffinity Technologies in the fourth quarter valued at $36,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.